Fundraising Overview - Jiangsu Kangzhong Digital Medical Technology Co., Ltd. raised a total of RMB 511,368,684.97 through the issuance of 22,032,257 shares at a price of RMB 23.21 per share, with a net amount of RMB 447,342,486.13 after deducting issuance costs [1] - As of June 30, 2025, the company has accumulated interest income of RMB 4,418,226.16 and received investment income of RMB 24,965,294.32, totaling RMB 29,383,520.48 [1] Fund Utilization - The company has spent RMB 310,088,509.94 on fundraising projects, with RMB 21,493,944.94 spent in the current year [1] - The remaining balance in the fundraising account as of June 30, 2025, is RMB 64,994,315.57 [1] Fund Management - The company has established a fundraising management system to ensure the proper use and storage of funds, adhering to relevant laws and regulations [1] - A tripartite supervision agreement has been signed with banks and the sponsor to ensure dedicated use of the funds [1] Cash Management - The company has approved the use of up to RMB 150 million of idle fundraising for cash management, with a usage period from the approval date until the next annual board meeting in 2025 [2] - The company has invested idle funds in short-term financial products with a maturity of less than 12 months [2] Project Status - The company has not changed the use of fundraising projects or transferred any projects during the reporting period [2] - The company has experienced delays in the construction of the flat panel detector production base and R&D service center, with completion dates extended to December 2025 due to various unforeseen factors [3]

Group 1 - The core viewpoint of the news highlights the performance and market position of Yirui Technology, noting its current stock price, market capitalization, and PE ratio compared to industry averages [1] - As of March 31, 2025, Yirui Technology has 5,745 shareholders, a decrease of 883 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, and other core components, having mastered four major sensor technologies [1] Group 2 - In the latest quarterly report for Q1 2025, Yirui Technology achieved a revenue of 482 million yuan, a year-on-year decrease of 1.92%, while net profit was 143 million yuan, an increase of 2.74%, with a gross profit margin of 48.92% [1] - The company's rolling PE ratio is 38.27, which is lower than the industry average of 49.20 and the industry median of 36.56, ranking 77th in the industry [2] - The industry average PE ratio is 49.20, with a median of 36.56, indicating that Yirui Technology is positioned below the average in terms of valuation metrics [2]

来源：金融界 5月6日，奕瑞科技今日收盘122.58元，上涨1.30%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到37.39倍，总市值175.37亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.90倍，行业中值36.41倍，奕瑞科技排 名第76位。 截至2025年一季报，共有47家机构持仓奕瑞科技，其中基金39家、其他8家，合计持股数8254.52万股， 持股市值94.43亿元。 奕瑞电子科技集团股份有限公司的主营业务是数字化X线探测器、高压发生器、组合式射线源、球管等 新核心部件的研发、生产、销售与服务。报告期内，公司量产的产品包括平板探测器和线阵探测器，并 已掌握非晶硅、IGZO、CMOS和柔性基板四大传感器技术，为公司进一步丰富产品线、服务多领域客 户、提高市场竞争力与品牌影响力打下坚实的基础。 最新一期业绩显示，2025年一季报，公司实现营业收入4.82亿元，同比-1.92%；净利润1.43亿元，同比 2.74%，销售毛利率48.92%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)76奕瑞科技37.3937.703.87175.37亿行业平均 48.9 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1][6][7]. Core Insights - The company's main business is stabilizing, with new technologies flourishing, as evidenced by the launch of various innovative products in the medical and industrial sectors [3][4]. - The company reported a revenue of 1.831 billion yuan in 2024, a slight decrease of 1.74% year-on-year, with a net profit of 465 million yuan, down 23.43% year-on-year [3]. - The company is actively expanding its product matrix and has made significant advancements in the development of new core components and X-ray comprehensive solutions [4][6]. Financial Performance Summary - In 2024, the company achieved a revenue of 1.831 billion yuan, with a gross margin of 50.11% and a net margin of 24.59% [3]. - For Q1 2025, the company reported a revenue of 482 million yuan, a year-on-year decrease of 1.92%, but a net profit increase of 2.74% to 143 million yuan [3]. - The company forecasts revenues of 2.162 billion yuan in 2025, with a projected net profit of 574 million yuan, reflecting a growth rate of 18% and 23% respectively [5][6]. Product Development and Market Position - The company has successfully launched several new products, including high-resolution detectors and various X-ray sources, enhancing its competitive edge in the market [3][4]. - The company is focusing on R&D investments in CMOS detectors, CT detectors, and photon counting detectors, which are expected to drive future growth [3][4]. - The company aims to strengthen its position as a core supplier of digital X-ray components and comprehensive solutions through continuous innovation and global business expansion [6].